Sugi Predict

Sugi Predict / Compounds / SCHEMBL1438328

SCHEMBL1438328

SCHEMBL1438328

O=C1NCc2ccc(I)cc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP2 O95551 2/20 0.59
▸ CLK4 Q9HAZ1 3/20 0.58
▸ NTRK2 Q16620 2/20 0.58
▸ DYRK1B Q9Y463 2/20 0.58
▸ TYRO3 Q06418 1/20 0.58
▸ NTRK1 P04629 2/20 0.56
▸ FLT3 P36888 2/20 0.56
▸ GSK3B P49841 2/20 0.56
▸ JAK2 O60674 1/20 0.56
▸ MET P08581 1/20 0.56
▸ FGFR1 P11362 1/20 0.56
▸ PRKACA P17612 1/20 0.56
▸ KDR P35968 1/20 0.56
▸ MAP2K2 P36507 1/20 0.56
▸ MAP2K1 Q02750 1/20 0.56
▸ MST1R Q04912 1/20 0.56
▸ NTRK3 Q16288 1/20 0.56
▸ CAMK1D Q8IU85 1/20 0.56
▸ CA12 O43570 1/20 0.55
▸ CA9 Q16790 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765133 1.00 TDP2 (0.59) TDP2CLK4NTRK2DYRK1BTYRO3
SCHEMBL1438853 0.86 TDP2 (0.58) TDP2CLK4NTRK2DYRK1BTYRO3
SCHEMBL793665 0.82 PARP10 (0.64) TDP2PARP1PARP10F7F3
SCHEMBL1233219 0.78 NTRK2 (0.56) TDP2CLK4NTRK2DYRK1BTYRO3
SCHEMBL17082844 0.78 CLK4 (0.56) TDP2CLK4NTRK2DYRK1BTYRO3
SCHEMBL4499446 0.78 NTRK2 (0.56) TDP2CLK4NTRK2DYRK1BTYRO3
SCHEMBL391991 0.78 PARP10 (0.68) TDP2CLK4NTRK2DYRK1BTYRO3
SCHEMBL149199 0.78 PARP10 (0.68) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL21267639 0.78 CLK4 (0.56) TDP2CLK4NTRK2DYRK1BTYRO3
SCHEMBL1760377 0.78 NTRK2 (0.74) TDP2CLK4NTRK2DYRK1BTYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655296-A1 CBL-B INHIBITORS Aurigene Oncology Limited (IN) 2025-12-03 — — EP disclosed
WO-2024156938-A1 CBL-B INHIBITORS ORION CORPORATION (FI) 2024-08-02 — — WO disclosed
US-11603349-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD (AU) 2023-03-14 — — US disclosed
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD (AU) 2021-08-12 — — US disclosed
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD (AU) 2021-08-12 — — US disclosed
US-11014873-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD. (AU) 2021-05-25 — — US disclosed
US-11014873-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD. (AU) 2021-05-25 — — US disclosed
EP-3788041-A1 NOVEL COMPOUNDS Inflazome Limited (IE) 2021-03-10 — — EP disclosed
WO-2021041866-A1 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-03-04 — — WO disclosed
US-20200055814-A1 ANTI-FIBROTIC COMPOUNDS SHIRE HUMAN GENETIC THERAPIES, INC. 2020-02-20 — — US disclosed
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-10 — — US disclosed
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-10 — — US disclosed
WO-2011025565-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 — — WO disclosed
WO-2011025565-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 — — WO disclosed
WO-2010065717-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-06-10 — — WO disclosed
WO-2010065717-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-06-10 — — WO disclosed
WO-2010054279-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2010-05-14 — — WO disclosed
WO-2010054278-A2 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2010-05-14 — — WO disclosed
US-7022724-B2 Cognition enhancing derivatives of isoxazole triazoloindane GABA-A α5 receptor subunit ligands MERCK SHARP & DOHME LTD. (GB) 2006-04-04 — — US disclosed
US-20040058970-A1 Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands MERCK SHARP & DOHME LTD. (GB) 2004-03-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603349-B2 Anti-fibrotic compounds TGFB1, SMAD3, TGFB2 TDP2 3802/4885CLK4 4503/4885NTRK2 2972/4885
US-20040058970-A1 Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands GABRA5, GABRA1, GABRB1 TDP2 2936/4885CLK4 3313/4885NTRK2 259/4885
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS TGFB1, SMAD3, TGFB2 TDP2 3802/4885CLK4 4503/4885NTRK2 2972/4885
US-11014873-B2 Anti-fibrotic compounds TGFB1, SMAD3, SMAD2 TDP2 3856/4885CLK4 4468/4885NTRK2 2995/4885
US-20200055814-A1 ANTI-FIBROTIC COMPOUNDS TGFB1, SMAD3, SMAD2 TDP2 4025/4885CLK4 3980/4885NTRK2 2331/4885
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS SERPINC1, F9, F8 TDP2 1998/4885CLK4 4605/4885NTRK2 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.